Showing results (311-320 of 498) with videos related to

Sort By:
Pageof 50
Blood|October 21, 2018
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapyShigeru Kusumoto, Luca Arcaini, Xiaonan Hong, et al.
Oncology Reports|April 6, 2005
Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinomaJung Han Kim, Chul Won Jung, Yeon Hee Cho, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II TrialMatthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
International Journal of Hematology|June 29, 2019
The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scoresSeok Jae Huh, Sung Yong Oh, Suee Lee, et al.
British Journal of Haematology|March 13, 2014
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaMichinori Ogura, Kiyoshi Ando, Tatsuya Suzuki, et al.
Leukemia Research|August 26, 2006
Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphomaJeeyun Lee, Won Seog Kim, Kihyun Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphomaKen Ohmachi, Nozomi Niitsu, Toshiki Uchida, et al.
Leukemia & Lymphoma|April 23, 2004
Intestinal lymphoma: exploration of the prognostic factors and the optimal treatmentJeeyun Lee, Won Seog Kim, Kihyun Kim, et al.
American Journal of Clinical Oncology|December 15, 2004
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimenSe Hoon Park, Won Ki Kang, Hyo Rak Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2024
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell LymphomasWon Seog Kim, Jake Shortt, Pier Luigi Zinzani, et al.
Pageof 50